Target intelligence / Profile preview

Penicillin-binding proteins 1A, 1B, 3, and 4 (Escherichia coli) (PBPs (1A, 1B, 3, 4))

Target
PBPs (1A, 1B, 3, 4)
Molecular classification
Enzyme, DD-transpeptidase, DD-carboxypeptidase, Glycosyltransferase
01

Overview

Penicillin-binding proteins (PBPs) 1A, 1B, 3, and 4 are essential enzymes in Escherichia coli that catalyze the final stages of peptidoglycan biosynthesis, which is critical for maintaining the structural integrity and shape of the bacterial cell wall [1, 2, 5]. PBP1A (mrcA) and PBP1B (mrcB) are high-molecular-weight Class A bifunctional enzymes possessing both transglycosylase and transpeptidase activities; they are functionally redundant, but the presence of at least one is required for cell viability [3, 9]. PBP3 (ftsI) is a Class B transpeptidase specifically required for the formation of the division septum, and its inhibition leads to the arrest of cell division and the formation of long filaments [10, 12]. PBP4 (dacB) is a low-molecular-weight Class C enzyme with DD-carboxypeptidase and endopeptidase activities involved in the remodeling and maturation of the peptidoglycan layer [1, 9]. These proteins are the primary therapeutic targets for beta-lactam antibiotics, including penicillins, cephalosporins, and carbapenems, which act as suicide inhibitors by covalently binding to the active site serine [5, 8, 10]. Inhibition of these PBPs disrupts cell wall assembly, leading to osmotic instability, cell lysis, and bacterial death [4, 10].

Other names
mrcA (PBP1A)ponA (PBP1A)mrcB (PBP1B)ponB (PBP1B)ftsI (PBP3)pbpB (PBP3)dacB (PBP4)DD-transpeptidaseDD-carboxypeptidasePeptidoglycan glycosyltransferase
02

Mechanism of action

Covalent inhibition of the transpeptidase domain by acting as a structural analog of the D-alanyl-D-alanine terminus of peptidoglycan precursors, thereby preventing cell wall cross-linking and leading to bacterial lysis [2, 5, 8, 10].

03

Biological functions

Peptidoglycan biosynthesisCell wall cross-linkingCell divisionCell elongationPeptidoglycan remodeling
04

Disease associations

Infection
05

Safety considerations

Antibiotic resistance (PBP mutations, beta-lactamase production)Beta-lactam hypersensitivity/allergyGastrointestinal dysbiosis
06

Interacting drugs

Ampicillin

12 more in the full profile.

07

Biomarkers

Minimum Inhibitory Concentration (MIC)PBP occupancy (Bocillin-FL binding)Bacterial filamentationSpheroplast formation

Beyond the preview

Go deeper on Penicillin-binding proteins 1A, 1B, 3, and 4 (Escherichia coli) (PBPs (1A, 1B, 3, 4)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Penicillin-binding proteins 1A, 1B, 3, and 4 (Escherichia coli) (PBPs (1A, 1B, 3, 4)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call